Gabapentin for the treatment of visual hallucination associated with Parkinson's disease

Not Applicable

Recruiting

• Conditions: Parkinson' s disease; s disease, Visual hallucinations, Gabapentin, Quetiapine

• Registration Number: TCTR20181220008
• Lead Sponsor: Research and Development Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-12-20
• Study Completion: 2020-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

PD patients who are being the visual hallucination for at least 1 months duration.

Exclusion Criteria

1. Pateints with communication problem
2. Patients who are taking gabapentin or antipsychotic medications

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
visual hallucination 4 weeks after take each medication interview

Secondary Outcome Measures

Name	Time	Method
/A N/A N/A